Ignite Creation Date:
2025-12-25 @ 1:23 AM
Ignite Modification Date:
2026-02-24 @ 1:44 AM
Study NCT ID:
NCT02280993
Status:
UNKNOWN
Last Update Posted:
2018-03-13
First Post:
2014-08-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients
Sponsor:
Marjolein Spiering
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
Transplant BRaVE
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |